Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: Potential sources of metabolic drug interactions

Toxicology

Volumn 270, Issue 2-3, 2010, Pages 59-65

  Zhu, Hao Jie ^a   Appel, David I ^b   Peterson, Yuri K ^b   Wang, Zichao ^c   Markowitz, John S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c School of Business and Economics   (United States)

Author keywords

Carboxylesterase 1; Drug drug interactions; Inhibitor; Metabolism; Methylphenidate

Indexed keywords

4 NITROPHENYL ACETATE; ACETIC ACID DERIVATIVE; ARIPIPRAZOLE; ATOMOXETINE; CARBOXYLESTERASE 1 INHIBITOR; CLOZAPINE; ESTERASE INHIBITOR; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; METHYLPHENIDATE; NORCLOZAPINE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; THIORIDAZINE; UNCLASSIFIED DRUG; ZIPRASIDONE;

ANIMAL EXPERIMENT; ARTICLE; CATALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG IDENTIFICATION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; DRUG TOLERABILITY; ENZYME INHIBITION; ENZYME SUBSTRATE COMPLEX; IC 50; IN VITRO STUDY; MALE; METABOLIC INHIBITION; MOLECULAR MODEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RACEMIC MIXTURE;

ANIMALS; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CARBOXYLIC ESTER HYDROLASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CLUSTER ANALYSIS; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; HYDROLYSIS; MALE; METABOLIC DETOXICATION, DRUG; METHYLPHENIDATE; MICE; MODELS, MOLECULAR; PHARMACEUTICAL PREPARATIONS; PIPERAZINES; QUINOLONES;

ANIMALIA; MUS;

EID: 77950022835     PISSN: 0300483X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tox.2010.01.009     Document Type: Article

References (37)

1. Adis International Methylphenidate interaction: interaction with concomitant aripiprazole (first report) leading to acute dystonia in a child: case report. Reactions 2007, 1136:20.
2. Berecz R., de la Rubia A., Dorado P., Fernandez-Salguero P., Dahl M.L., A L.L. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur. J. Clin. Pharmacol. 2003, 59:45-50.
3. Charlier C., Broly F., Lhermitte M., Pinto E., Ansseau M., Plomteux G. Polymorphisms in the CYP 2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther. Drug Monit. 2003, 25:738-742.
4. Christman A.K., Fermo J.D., Markowitz J.S. Atomoxetine, a novel treatment for attention-deficit-hyperactivity disorder. Pharmacotherapy 2004, 24:1020-1036.
5. Elia J., Ambrosini P.J., Rapoport J.L. Treatment of attention-deficit-hyperactivity disorder. N. Engl. J. Med. 1999, 340:780-788.
6. Ferranti J., Horvath M.M., Cozart H., Whitehurst J., Eckstrand J. Reevaluating the safety profile of pediatrics: a comparison of computerized adverse drug event surveillance and voluntary reporting in the pediatric environment. Pediatrics 2008, 121:e1201-e1207.
7. Fleming C.D., Bencharit S., Edwards C.C., Hyatt J.L., Tsurkan L., Bai F., Fraga C., Morton C.L., Howard-Williams E.L., Potter P.M., Redinbo M.R. Structural insights into drug processing by human carboxylesterase 1: tamoxifen, mevastatin, and inhibition by benzil. J. Mol. Biol. 2005, 352:165-177.
8. Grunder G., Fellows C., Janouschek H., Veselinovic T., Boy C., Brocheler A., Kirschbaum K.M., Hellmann S., Spreckelmeyer K.M., Hiemke C., Rosch F., Schaefer W.M., Vernaleken I. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. Am. J. Psychiatry 2008, 165:988-995.
9. Gupta R.C., Dettbarn W.D. Role of carboxylesterases in the prevention and potentiation of N-methylcarbamate toxicity. Chem. Biol. Interact. 1993, 87:295-303.
10. Hansen L.B., Larsen N.E. Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment. Psychopharmacology (Berl) 1977, 53:127-130.
11. Hansen L.B., Larsen N.E., Vestergard P. Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects. Psychopharmacology (Berl) 1981, 74:306-309.
12. Imai T., Taketani M., Shii M., Hosokawa M., Chiba K. Substrate specificity of carboxylesterase isozymes and their contribution to hydrolase activity in human liver and small intestine. Drug Metab. Dispos. 2006, 34:1734-1741.
13. Kirschbaum K.M., Muller M.J., Malevani J., Mobascher A., Burchardt C., Piel M., Hiemke C. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J. Biol. Psychiatry 2008, 9:212-218.
14. LeVasseur N.L., Zhu H.J., Markowitz J.S., DeVane C.L., Patrick K.S. Enantiospecific gas chromatographic-mass spectrometric analysis of urinary methylphenidate: implications for phenotyping. J. Chromatogr. B: Analyt. Technol. Biomed. Life Sci. 2008, 862:140-149.
15. LLerena A.L., Dorado P., Berecz R., Gonzalez A.P., Penas L.E.M. Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. Eur. J. Clin. Pharmacol. 2004, 59:869-873.
16. Markowitz J.S., Morrison S.D., DeVane C.L. Drug interactions with psychostimulants. Int. Clin. Psychopharmacol. 1999, 14:1-18.
17. Markowitz J.S., Patrick K.S. Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder. Clin. Pharmacokinet. 2001, 40:753-772.
18. Maxwell D.M., Brecht K.M. Carboxylesterase: specificity and spontaneous reactivation of an endogenous scavenger for organophosphorus compounds. J. Appl. Toxicol. 2001, 21(Suppl. 1):S103-S107.
19. Nakamura A., Mihara K., Nagai G., Suzuki T., Kondo T. Pharmacokinetic and pharmacodynamic interactions between carbamazepine and aripiprazole in patients with schizophrenia. Ther. Drug Monit. 2009, 31:575-578.
20. Patrick K.S., Caldwell R.W., Ferris R.M., Breese G.R. Pharmacology of the enantiomers of threo-methylphenidate. J. Pharmacol. Exp. Ther. 1987, 241:152-158.
21. Patrick K.S., Gonzalez M.A., Straughn A.B., Markowitz J.S. New methylphenidate formulations for the treatment of attention-deficit/hyperactivity disorder. Expert Opin. Drug Deliv. 2005, 2:121-143.
22. Patrick K.S., Kilts C.D., Breese G.R. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. J. Med. Chem. 1981, 24:1237-1240.
23. Patrick K.S., Markowitz J.S. Pharmacology of methylphenidate, amphetamine enantiomers and pemoline in attention-deficit hyperactivity disorder. Hum. Psychopharmacol. 1997, 12:527-546.
24. Patrick K.S., Straughn A.B., Minhinnett R.R., Yeatts S.D., Herrin A.E., DeVane C.L., Malcolm R., Janis G.C., Markowitz J.S. Influence of ethanol and gender on methylphenidate pharmacokinetics and pharmacodynamics. Clin. Pharmacol. Ther. 2007, 81:346-353.
25. Ross M.K., Crow J.A. Human carboxylesterases and their role in xenobiotic and endobiotic metabolism. J. Biochem. Mol. Toxicol. 2007, 21:187-196.
26. Satoh T., Taylor P., Bosron W.F., Sanghani S.P., Hosokawa M., La Du B.N. Current progress on esterases: from molecular structure to function. Drug Metab. Dispos. 2002, 30:488-493.
27. Smith P.B., Benjamin D.K., Murphy M.D., Johann-Liang R., Iyasu S., Gould B., Califf R.M., Li J.S., Rodriguez W. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics 2008, 122:e628-e633.
28. Srinivas N.R., Hubbard J.W., Korchinski E.D., Midha K.K. Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans. Pharm. Res. 1993, 10:14-21.
29. Sun Z., Murry D.J., Sanghani S.P., Davis W.I., Kedishvili N.Y., Zou Q., Hurley T.D., Bosron W.F. Methylphenidate is stereoselectively hydrolyzed by human carboxylesterase CES1A1. J. Pharmacol. Exp. Ther. 2004, 310:469-476.
30. Thanacoody R.H., Daly A.K., Reilly J.G., Ferrier I.N., Thomas S.H. Factors affecting drug concentrations and QT interval during thioridazine therapy. Clin. Pharmacol. Ther. 2007, 82:555-565.
31. Wheelock C.E., Nakagawa Y., Akamatsu M., Hammock B.D. Use of classical and 3-D QSAR to examine the hydration state of juvenile hormone esterase inhibitors. Bioorg. Med. Chem. 2003, 11:5101-5116.
32. Yang D., Pearce R.E., Wang X., Gaedigk R., Wan Y.J., Yan B. Human carboxylesterases HCE1 and HCE2: ontogenic expression, inter-individual variability and differential hydrolysis of oseltamivir, aspirin, deltamethrin and permethrin. Biochem. Pharmacol. 2009, 77:238-247.
33. Zeni C.P., Tramontina S., Ketzer C.R., Pheula G.F., Rohde L.A. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial. J. Child Adolesc. Psychopharmacol. 2009, 19:553-561.
34. Zhu H.J., Appel D.I., Jiang Y., Markowitz J.S. Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab. Dispos. 2009, 37:1819-1825.
35. Zhu H.J., Appel D.I., Johnson J.A., Chavin K.D., Markowitz J.S. Role of carboxylesterase 1 and impact of natural genetic variants on the hydrolysis of trandolapril. Biochem. Pharmacol. 2009, 77:1266-1272.
36. Zhu H.J., Markowitz J.S. Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab. Dispos. 2009, 37:264-267.
37. Zhu H.J., Patrick K.S., Yuan H.J., Wang J.S., Donovan J.L., DeVane C.L., Malcolm R., Johnson J.A., Youngblood G.L., Sweet D.H., Langaee T.Y., Markowitz J.S. Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activity in man: clinical significance and molecular basis. Am. J. Hum. Genet. 2008, 82:1241-1248.